Anderson RT, Keating KN, Doll HA, Camacho F (2015) The hand-foot skin reaction and quality of life questionnaire: an assessment tool for oncology. Oncologist 20:831–838. https://doi.org/10.1634/theoncologist.2014-0219

Article  PubMed  PubMed Central  Google Scholar 

Andonova VY, Peneva PT, Apostolova EG et al (2017) Carbopol hydrogel/sorbitan monostearate-almond oil based organogel biphasic formulations: preparation and characterization of the bigels. Trop J Pharm Res 16:1455–1463. https://doi.org/10.4314/tjpr.v16i7.1

Article  CAS  Google Scholar 

Baldo BA, Pham NH (2013) Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev 32(3–4):723–761. https://doi.org/10.1007/s10555-013-9447-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ceglio WQGW, Rebeis MM, Santana MF et al (2022) Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital. An Bras Dermatol 97(1):14–21. https://doi.org/10.1016/j.abd.2021.05.007

Article  PubMed  Google Scholar 

Charalambous A, Tsitsi T, Astras G et al (2021) A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD). Eur J Oncol Nurs 50:101866. https://doi.org/10.1016/j.ejon.2020.101866

Article  PubMed  Google Scholar 

Chen JC, Wang JC, Pan YX et al (2020) Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial. Am J Cancer Res 10(5):1467–1476

CAS  PubMed  PubMed Central  Google Scholar 

Danaei M, Dehghankhold M, Ataei S et al (2018) Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 10:57. https://doi.org/10.3390/pharmaceutics10020057

Article  CAS  PubMed  PubMed Central  Google Scholar 

Devereaux PJ, Manns BJ, Ghali WA et al (2001) Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 285:2000–2003. https://doi.org/10.1001/jama.285.15.2000

Article  CAS  PubMed  Google Scholar 

Dhabu PM, Akamanchi KG (2002) A stability-indicating HPLC method to determine celecoxib in capsule formulations. Drug Dev Ind Pharm 28(7):815–821. https://doi.org/10.1081/ddc-120005627

Article  CAS  PubMed  Google Scholar 

Hager E, Chen J, Zhao L (2022) Minireview: parabens exposure and breast cancer. Int J Environ Res Public Health 19(3):1873. https://doi.org/10.3390/ijerph19031873

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haynes D, Ortega-Loayza AG (2022) Adverse cutaneous reactions to chemotherapeutic drugs. Clin Dermatol 38(6):712–728. https://doi.org/10.1016/j.clindermatol.2020.06.007

Article  Google Scholar 

He X, Wang J, Wang Q et al (2022) P38 MAPK, NF-κB, and JAK-STAT3 signaling pathways involved in capecitabine-induced hand-foot syndrome via interleukin 6 or interleukin 8 abnormal expression. Chem Res Toxicol 35(3):422–430. https://doi.org/10.1021/acs.chemrestox.1c00317

Article  CAS  PubMed  Google Scholar 

Huang XZ, Chen Y, Chen WJ et al (2018) Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome. Int J Cancer 142(12):2567–2577. https://doi.org/10.1002/ijc.31269

Article  CAS  PubMed  Google Scholar 

ICH Topic Q 1 A (R2), Stability testing of new drug substances and products, August 2003, CPMP/ICH/2736/99, https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-products-step-5_en.pdf

Jung S, Sehouli J, Chekerov R et al (2017) Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®). Support Care Cancer 25(11):3545–3549. https://doi.org/10.1007/s00520-017-3781-x

Article  CAS  PubMed  Google Scholar 

Karimi E, Gharib B, Navidpour L, Afshar M (2019) Clinical efficacy of a topical polyherbal formulation in the management of fluorouracil -associated hand-foot syndrome. J Herb Med 17–18:100270. https://doi.org/10.1016/j.hermed.2019.100270

Article  Google Scholar 

Kassis V, Søndergaard J (1982) Heat-separation of normal human skin for epidermal and dermal prostaglandin analysis. Arch Dermatol Res 273:301–306. https://doi.org/10.1007/BF00409259

Article  CAS  PubMed  Google Scholar 

Khan MUA, Izwan Abd Razaq S, Mehboob H et al (2021) Antibacterial and hemocompatible pH-responsive hydrogel for skin wound healing application: in vitro drug release. Polymers 13:3703. https://doi.org/10.3390/polym13213703

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwakman JJM, Elshot YS, Punt CJA et al (2020) Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev 14(1):442. https://doi.org/10.4081/oncol.2020.442

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lan TC, Tsou PH, Tam KW et al (2021) Effect of urea cream on hand-foot syndrome in patients receiving chemotherapy: a meta-analysis. Cancer Nurs. https://doi.org/10.1097/NCC.0000000000001008

Article  PubMed  Google Scholar 

Lin E, Morris JS, Ayers GD (2002) Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncol (Williston Park) 16(12 Suppl No 14):31–37

Google Scholar 

Macedo LT, Lima JPN, Vieira dos Santos L, Sasse AD (2014) Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 22(6):1585–1593. https://doi.org/10.1007/s00520-014-2129-z

Article  PubMed  Google Scholar 

Meadows KL, Rushing C, Honeycutt W et al (2015) Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer 23(5):1311–1319. https://doi.org/10.1007/s00520-014-2465-z

Article  PubMed  Google Scholar 

Moher D, Hopewell S, Schulz KF et al (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials. J Clin Epidemiol 63:e1-37. https://doi.org/10.1016/j.jclinepi.2010.03.004

Article  PubMed  Google Scholar 

On J, Park HA, Yoo S (2022) Development of a prediction models for chemotherapy-induced adverse drug reactions. A retrospective observational study using electronic health records. Eur J Oncol Nurs 56:102066. https://doi.org/10.1016/j.ejon.2021.102066

Article  PubMed  Google Scholar 

Quiñones OG, Mata dos Santos HA, Kibwila DM et al (2014) In vitro and in vivo influence of penetration enhancers in the topical application of celecoxib. Drug Dev Ind Pharm. 40(9):1180–9. https://doi.org/10.3109/03639045.2013.809731

Article  CAS  PubMed  Google Scholar 

Rodríguez-Garzotto A, Iglesias-Docampo L, Ruppen I et al (2022) Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies. Ther Adv Med Oncol 14:17588359221086912. https://doi.org/10.1177/17588359221086911

Article  PubMed  PubMed Central  Google Scholar 

Salem HF, Kharshoum RM, Sayed OM et al (2018) Formulation design and optimization of novel soft glycerosomes for enhanced topical delivery of celecoxib and cupferron by Box-Behnken statistical design. Drug Dev Ind Pharm 44(11):1871–1884. https://doi.org/10.1080/03639045.2018.1504963

Article  CAS  PubMed  Google Scholar 

Santhosh A, Kumar A, Pramanik R, and et al. (2022) Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study) Trials 23(1):420. https://doi.org/10.1186/s13063-022-06353-2.

Saxena P, Sharma PK, Purohit P (2020) A journey of celecoxib from pain to cancer. Prostaglandins Other Lipid Mediat 147:106379. https://doi.org/10.1016/j.prostaglandins.2019.106379

Article  CAS  PubMed  Google Scholar 

Sharkawy A, Casimiro FM, Barreiro MF, Rodrigues AE (2020) Enhancing trans-resveratrol topical delivery and photostability through entrapment in chitosan/gum Arabic Pickering emulsions, International Journal of Biological Macromolecules. Int J Biol Macromol 147:150–159. https://doi.org/10.1016/j.ijbiomac.2020.01.057

Article  CAS  PubMed  Google Scholar 

Singh VK, Anis A, Banerjee I et al (2014) Preparation and characterization of novel carbopol based bigels for topical delivery of metronidazole for the treatment of bacterial vaginosis. Mater Sci Eng C Mater Biol Appl 44:151–158. https://doi.org/10.1016/j.msec.2014.08.026

Article  CAS  PubMed  Google Scholar 

Templeton AJ, Ribi K, Surber C et al (2014) Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 23(3):244–249. https://doi.org/10.1016/j.breast.2014.02.005

Article  PubMed  Google Scholar 

Wagner S, Lang S, Popp T et al (2019) Evaluation of selective and non-selective cyclooxygenase inhibitors on sulfur mustard-induced pro-inflammatory cytokine formation in normal human epidermal keratinocytes. Toxicol Lett 312:109–117. https://doi.org/10.1016/j.toxlet.2019.03.012

Article  CAS  PubMed  Google Scholar 

Wong TW (2016) Microwave-aided skin drug penetration and retention of 5-fluorouracil-loaded ethosomes. Expert Opin Drug Deliv 13(9):1209–1219. https://doi.org/10.1080/17425247.2016.1193152

Article  CAS  PubMed  Google Scholar 

World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects, (2013). https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2013-JAMA.pdf

Zhang RX, Wu XJ, Lu SX et al (2011) The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol 137(6):953–957. https://doi.org/10.1007/s00432-010-0958-9

Article  CAS  PubMed  Google Scholar 

Zhang RX, Wu XJ, Wan DS et al (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23(5):1348–1353. https://doi.org/10.1093/annonc/mdr400

Article  CAS  PubMed